» Articles » PMID: 37277211

Characterisation of Patients with Axial Psoriatic Arthritis and Patients with Axial Spondyloarthritis and Concomitant Psoriasis in the SCQM Registry

Overview
Journal RMD Open
Specialty Rheumatology
Date 2023 Jun 5
PMID 37277211
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Within the spectrum of spondyloarthritides, axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) present with overlapping features. Axial involvement in PsA (axial PsA) is treated according to recommendations for axSpA, as specific studies in axial PsA are scarce. We compared characteristics of patients with axSpA (particularly of patients with axSpA and concomitant psoriasis (pso)) with those of patients with axial PsA.

Methods: Patients with axSpA and PsA in the Swiss Clinical Quality Management (SCQM) registry were included if information on pso and axial involvement was available. Patients with AxSpA were stratified by axSpA with and without pso (axSpA±pso) and patients with PsA were stratified to axial PsA or strictly peripheral PsA.

Results: Previous or current psoriasis was observed in 479/4489 patients with axSpA (10.7%). Of 2631 patients with PsA, 1153 (43.8%) presented with axial involvement (opinion of the treating rheumatologist). Compared with patients with axSpA+pso, patients with axial PsA were older at symptom onset and at inclusion in SCQM, were less frequently HLA-B27 positive, had back pain less frequently and a higher prevalence of dactylitis and peripheral arthritis. A positive family history of pso or PsA was more frequent in axial PsA, while a positive family history of axSpA was more frequent in patients with axSpA+pso. Disease activity, function and mobility were comparable in axSpA+pso versus axial PsA.

Conclusion: Patients with axial PsA differ from patients with axSpA+pso in important demographic and clinical characteristics, and genetically, but present with a comparable disease burden. Treatment studies specifically dedicated to axial PsA seem warranted.

Citing Articles

Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry.

Lopalco G, Morrone M, Atzeni F, Bazzani C, Bianchi F, Cantatore F Ther Adv Musculoskelet Dis. 2025; 17:1759720X251315138.

PMID: 39897378 PMC: 11783553. DOI: 10.1177/1759720X251315138.


Impact of disease manifestations on first biologic drug survival in axial spondyloarthritis: a real-life Canadian study.

Hurtubise R, Rohekar S, Haroon N, Baskurt Z, Chim T, Zummer M Rheumatol Adv Pract. 2025; 9(1):rkaf004.

PMID: 39886539 PMC: 11780884. DOI: 10.1093/rap/rkaf004.


Axial Disease in Psoriatic Arthritis: A Challenging Domain in Clinical Practice.

Alascio L, Azuaga-Pinango A, Frade-Sosa B, Sarmiento-Monroy J, Ponce A, Farietta S Diagnostics (Basel). 2024; 14(15).

PMID: 39125513 PMC: 11311426. DOI: 10.3390/diagnostics14151637.


Impact of initiation of targeted therapy on the use of psoriatic arthritis-related treatments and healthcare consumption: a cohort study of 9793 patients from the French health insurance database (SNDS).

Pina Vegas L, Iggui S, Sbidian E, Claudepierre P RMD Open. 2024; 10(3).

PMID: 39117446 PMC: 11409354. DOI: 10.1136/rmdopen-2024-004631.

References
1.
Poddubnyy D, Baraliakos X, Van den Bosch F, Braun J, Coates L, Chandran V . Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Ther Adv Musculoskelet Dis. 2022; 13:1759720X211057975. PMC: 8721378. DOI: 10.1177/1759720X211057975. View

2.
Gladman D . Axial Psoriatic Arthritis. Curr Rheumatol Rep. 2021; 23(6):35. DOI: 10.1007/s11926-021-00999-8. View

3.
Stekhoven D, Scherer A, Nissen M, Grobety V, Yawalkar N, Villiger P . Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping. Clin Rheumatol. 2017; 36(9):2035-2043. PMC: 5554477. DOI: 10.1007/s10067-017-3637-2. View

4.
Ciurea A, Scherer A, Weber U, Neuenschwander R, Tamborrini G, Exer P . Age at symptom onset in ankylosing spondylitis: is there a gender difference?. Ann Rheum Dis. 2014; 73(10):1908-10. DOI: 10.1136/annrheumdis-2014-205613. View

5.
Dougados M, Baeten D . Spondyloarthritis. Lancet. 2011; 377(9783):2127-37. DOI: 10.1016/S0140-6736(11)60071-8. View